{"id":"full-course-of-pd-1-pd-l1-blockades","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Fatigue"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"10-20","effect":"Nausea"},{"rate":"3-5","effect":"Immune-related pneumonitis"},{"rate":"2-5","effect":"Immune-related hepatitis"},{"rate":"1-3","effect":"Immune-related colitis"},{"rate":"10-20","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PD-1 (programmed death receptor 1) and PD-L1 (programmed death ligand 1) are immune checkpoint proteins that suppress T-cell function. Blocking these interactions prevents tumor cells from inactivating cytotoxic T lymphocytes, allowing the immune system to recognize and eliminate cancer cells. This approach has demonstrated efficacy across multiple solid and hematologic malignancies.","oneSentence":"PD-1/PD-L1 blockade releases the brakes on the immune system by inhibiting checkpoint proteins that cancer cells use to evade T-cell attack, thereby restoring anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:35.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (specific indications under investigation in phase 3 trials)"}]},"trialDetails":[{"nctId":"NCT06675214","phase":"PHASE3","title":"Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-07-30","conditions":"Nasopharyngeal Carcinoma, De-escalation Therapy","enrollment":586},{"nctId":"NCT06092957","phase":"PHASE3","title":"Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-09","conditions":"Nasopharyngeal Carcinoma, De-escalation Therapy","enrollment":504}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Full course of PD-1/PD-L1 blockades","genericName":"Full course of PD-1/PD-L1 blockades","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PD-1/PD-L1 blockade releases the brakes on the immune system by inhibiting checkpoint proteins that cancer cells use to evade T-cell attack, thereby restoring anti-tumor immunity. Used for Advanced or metastatic solid tumors (specific indications under investigation in phase 3 trials).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}